Entries by Max

Real-World OPTYX Study: Sustained Castration and Rapid Testosterone Recovery with Relugolix

/in /by

Relugolix (Orgovyx), the first oral androgen deprivation therapy approved for advanced prostate cancer, continues to show consistent performance in real-world settings. New data from the OPTYX study, a prospective observational analysis, provide further evidence on testosterone suppression, recovery, and PSA control in routine clinical practice. The study included 999 patients, predominantly with nonmetastatic disease and […]

Tipifarnib Shows Early Promise as an Adjuvant in Enzalutamide-Resistant Prostate Cancer

/in /by

Tipifarnib is an interesting repurposing candidate in advanced prostate cancer because it may interfere with a resistance mechanism that goes beyond androgen signaling alone. In a preclinical work presented during the AUA 2026 meeting, the drug reduced exosome release from aggressive castration-resistant prostate cancer cells, including 22Rv1 and CWR-R1, by about 30% at low dose, […]

ZNF281 Emerges as a Novel Driver and Therapeutic Target in Advanced Prostate Cancer

/in /by

ZNF281 is a Krüppel-type zinc-finger transcription factor previously implicated in cancer stemness, but its role in prostate cancer has remained largely unexplored. In a new study, researchers evaluated ZNF281 expression across human prostate cancer samples, including primary tumors, metastatic lymph nodes, and normal prostate tissue. The findings revealed significantly higher expression of ZNF281 in metastatic […]

NRG1-Driven Microenvironmental Resistance to PI3K Inhibition in Prostate Cancer

/in /by

Prostate cancer is driven not only by tumor genetics but also by dynamic interactions with the tumor microenvironment (TME). Although alterations in the PI3K pathway are common, especially in PTEN-deficient disease, clinical results with PI3K inhibitors, even when combined with androgen receptor (AR) blockade, have been underwhelming. New evidence suggests that resistance may be driven […]

Arginase 1 Suppression Makes Exercise Effective Against Prostate Cancer

/in /by

Exercise has consistently been linked to improved outcomes in prostate cancer, but the mechanisms behind this effect have remained unclear. A recent preclinical study provides a compelling explanation, identifying suppression of arginase 1 (Arg1) and modulation of arginine metabolism as key drivers of exercise-induced tumor control. Using a prostate-specific Pten-knockout mouse model, researchers observed that […]

Newsletter 23/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Summer is approaching, but research never stops! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​ Clinical Research Phase 3 Trial: The PROTEUS Trial […]

IVMT-Rx-4: A New Experimental Drug That May Help Block Prostate Cancer Spread to Bone

/in /by

IVMT-Rx-4 is a preclinical stage experimental compound being studied for advanced prostate cancer, especially for cancer that spreads to bone. The basic idea is to interfere with a protein called MDA-9/Syntenin. This protein seems to help prostate cancer cells invade tissue, communicate with their environment, and settle in bone. By blocking that pathway, IVMT-Rx-4 may […]

A Promising Drug Pair for Treatment-Resistant Prostate Cancer

/in , /by

A recent preclinical study points to a potentially important strategy for advanced prostate cancer: combining two already-known drugs to attack the disease from different angles at the same time. The work focused on metastatic castration-resistant prostate cancer, one of the hardest forms of prostate cancer to treat because it often adapts after standard hormonal therapies […]

Early Phase 1 Trial of GRPR-Targeted Theranostic DOTA-STR-17126

/in , , /by

A first-in-human imaging trial of DOTA-STR-17126 just started in Australia. It is an open-label, single-arm early phase 1 study enrolling up to 20 adults with advanced or metastatic prostate or breast cancer who have exhausted standard treatments. The trial uses a theranostic approach. Participants receive gallium-68 DOTA-STR-17126 for PET imaging to detect tumors expressing the […]

Phase 2 Trial of GV20-0251 With Anti-PD-1 Therapy in mCRPC

/in , , /by

GV20-0251 is an experimental antibody that blocks a new immune brake called IGSF8, and this phase 2 study tests it together with anti-PD-1 drugs in people with advanced solid tumors that no longer respond to standard treatment. The goal is to restore early innate immune signaling so checkpoint therapy works better in resistant cancers. From […]